Drug intelligence / Profile preview

Pigbak#2-PE38

Development stage
Unknown
Modality
Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics
Administration
Intratumoral (via Live *e. Coli* Vehicle In Preclinical Models)
01

Overview

Pigbak#2-PE38 is a **recombinant immunotoxin** designed as a fusion protein that combines the single-chain Fab antibody Pigbak#2, which binds in a TNF-α (tumor necrosis factor alpha)-dependent manner, with the cytotoxic PE38 domain derived from *Pseudomonas exotoxin A*. This fusion protein was engineered to be secreted by genetically modified *Escherichia coli* BL21(DE3) Δlpp, a "leaky" strain optimized for extracellular secretion. Pigbak#2-PE38 exhibits potent, selective, TNF-α-dependent cytotoxicity toward cancer cells, notably showing strong anti-tumor activity in murine melanoma models. The mechanism leverages the presence of TNF-α in the tumor microenvironment to enable cell-specific targeting and internalization, followed by delivery of the PE38 toxin that induces cell death via inhibition of protein synthesis. Delivery via intratumorally injected bacteria leads to accumulation in tumors, upregulation of TNF-α, and significant immunomodulatory and anti-tumor effects[1][2].

Other names
Pigbak#2-PE38
02

Targets

EEF2 (Eukaryotic elongation factor 2)TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on Pigbak#2-PE38.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pigbak#2-PE38.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call